Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection

BACKGROUND: Current treatment strategies for antibody-mediated renal allograft rejection (AMR) are not sufficiently effective. In most centers, “standard of care” treatment includes plasmapheresis (PPH) and IVIG preparations. Since several years, modern therapeutics targeting B cells and plasma cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Waiser, Johannes, Duerr, Michael, Schönemann, Constanze, Rudolph, Birgit, Wu, Kaiyin, Halleck, Fabian, Budde, Klemens, Lachmann, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083001/
https://www.ncbi.nlm.nih.gov/pubmed/27819032
http://dx.doi.org/10.1097/TXD.0000000000000604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083001/
https://www.ncbi.nlm.nih.gov/pubmed/27819032
http://dx.doi.org/10.1097/TXD.0000000000000604

Ejemplares similares